Advanced search
Publication Cover
OncoTargets and Therapy Volume 14, 2021 - Issue
Submit an article Journal homepage
84
Views
4
CrossRef citations to date
0
Altmetric
Case Report

Dramatic Responses of Recurrent Upper Urinary Tract Urothelial Carcinoma Harboring FGFR3 and TP53 Activating Mutations to Pembrolizumab in Combination with Erdafitinib: A Case Report

Xinjia Ding1 Department of Urology, The Affiliated Zhongshan Hospital of Dalian University, Dalian, 116001, People’s Republic of ChinaView further author information
,
Jianguo Zong2 The Institute for Translational Medicine, The Affiliated Zhongshan Hospital of Dalian University, Dalian, 116001, People’s Republic of ChinaView further author information
,
Xiang Li2 The Institute for Translational Medicine, The Affiliated Zhongshan Hospital of Dalian University, Dalian, 116001, People’s Republic of ChinaView further author information
,
Xiaoyan Bai2 The Institute for Translational Medicine, The Affiliated Zhongshan Hospital of Dalian University, Dalian, 116001, People’s Republic of ChinaView further author information
,
Bowen Tan2 The Institute for Translational Medicine, The Affiliated Zhongshan Hospital of Dalian University, Dalian, 116001, People’s Republic of ChinaView further author information
,
Weibing Sun1 Department of Urology, The Affiliated Zhongshan Hospital of Dalian University, Dalian, 116001, People’s Republic of ChinaORCID Iconhttps://orcid.org/0000-0002-4903-6851View further author information
ORCID Icon,
Ruoyu Wang2 The Institute for Translational Medicine, The Affiliated Zhongshan Hospital of Dalian University, Dalian, 116001, People’s Republic of ChinaCorrespondence[email protected]
View further author information
&
Yan Ding2 The Institute for Translational Medicine, The Affiliated Zhongshan Hospital of Dalian University, Dalian, 116001, People’s Republic of China;3 Department of Pediatrics, Boston Children’s Hospital, Harvard Medical School, Boston, MA, 02115, USACorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-7708-4391View further author information
ORCID Icon show all
Pages 2177-2183 | Published online: 25 Mar 2021

References

  • Babjuk M, Burger M, Zigeuner R, et al. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2013. Eur Urol. 2013;64:639–653. doi:10.1016/j.eururo.2013.06.003
  • Munoz JJ, Ellison LM. Upper tract urothelial neoplasms: incidence and survival during the last 2 decades. J Urol. 2000;164:1523–1525. doi:10.1097/00005392-200011000-00014
  • Cohen JL, Peyronnet B, Seisen T, Soukup V. SEER cancer statistics factsheets: bladder cancer. Available from: http://seer.cancer.gov/statfacts/html/urinb.html. Accessed June 12, 2020.
  • Miller NJ, Khaki AR, Diamantopoulos LN, et al. Histological subtypes and response to PD-1/PD-L1 blockade in advanced urothelial cancer: a retrospective study. J Urol. 2020;204:63–70. doi:10.1097/JU.0000000000000761
  • Kaag MG, O’Malley RL, O’Malley P, et al. Changes in renal function following nephroureterectomy may affect the use of perioperative chemotherapy. Eur Urol. 2010;58:581–587. doi:10.1016/j.eururo.2010.06.029
  • Bajorin DF, Dodd PM, Mazumdar M, et al. Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy. J Clin Oncol. 1999;17:3173–3181. doi:10.1200/jco.1999.17.10.3173
  • Hall MC, Womack S, Roehrborn CG, Carmody T, Erickstad MD, Roehrborn CG. Prognostic factors, recurrence, and survival in transitional cell carcinoma of the upper urinary tract: a 30-year experience in 252 patients. Urology. 1998;52:594–601. doi:10.1016/s0090-4295(98)00295-7
  • Kamai T, Shirataki H, Nakanishi K, et al. Increased Rac1 activity and Pak1 overexpression are associated with lymphovascular invasion and lymph node metastasis of upper urinary tract cancer. BMC Cancer. 2010;10:164. doi:10.1186/1471-2407-10-164
  • Yu X, Meng X, Xu M, et al. Celastrol ameliorates cisplatin nephrotoxicity by inhibiting NF-kappaB and improving mitochondrial function. EBioMedicine. 2018;36:266–280. doi:10.1016/j.ebiom.2018.09.031
  • Alavi SE, Muflih A, Akbarzadeh A, Akbarzadeh A. Cisplatin-loaded polybutylcyanoacrylate nanoparticles with improved properties as an anticancer agent. Int J Mol Sci. 2019;20:1531. doi:10.3390/ijms20071531
  • Sonpavde G, Watson D, Tourtellott M, et al. Administration of cisplatin-based chemotherapy for advanced urothelial carcinoma in the community. Clin Genitourin Cancer. 2012;10:1–5. doi:10.1016/j.clgc.2011.11.005
  • Sonpavde G, Galsky MD, Latini D. Cisplatin-ineligibleandchemotherapy-ineligible patients should be the focus of new drug development in patients with advanced bladder cancer. Clin Genitourin Cancer. 2014;12:71–73. doi:10.1016/j.clgc.2013.11.016
  • Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12:252–264. doi:10.1038/nrc3239
  • Rosenberg JE, Hoffman-Censits J, Necchi A, et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet. 2016;387:1909–1920. doi:10.1016/s0140-6736(16)00561-4
  • Massard C, Gordon MS, Sharma S, et al. Safety and efficacy of durvalumab (MEDI4736), an anti-programmed cell death ligand-1 immune checkpoint inhibitor, in patients with advanced urothelial bladder cancer. J Clin Oncol. 2016;34:3119–3125. doi:10.1200/jco.2016.67.9761
  • Balar AV, Castellano D, O’Donnell PH, et al. First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study. Lancet Oncol. 2017;18:1483–1492. doi:10.1016/s1470-2045(17)30616-2
  • Balar AV, Galsky MD, Rosenberg JE, et al. Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial. Lancet (London, England). 2017;389:67–76. doi:10.1016/s0140-6736(16)32455-2
  • Tate JG, Bamford S, Jubb C, et al. COSMIC: the catalogue of somatic mutations in cancer. Nucl Acids Res. 2019;47:D941–47. doi:10.1093/nar/gky1015
  • Palma N, Morris JC, Pal SK, Ross JS, Pal SK. Exceptional response to pazopanib in a patient with urothelial carcinoma harboring FGFR3 activating mutation and amplification. Eur Urol. 2015;68:168–170. doi:10.1016/j.eururo.2015.02.023
  • Loriot Y, Necchi A, Park SH, et al. Erdafitinib in locally advanced or metastatic urothelial carcinoma. N Engl J Med. 2019;381:338–348. doi:10.1056/NEJMoa1817323
  • Warner AB, Palmer JS, Shoushtari AN, et al. Long-term outcomes and responses to retreatment in patients with melanoma treated with PD-1 blockade. J Clin Oncol. 2020;38:1655–1663. doi:10.1200/jco.19.01464

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.